Angiomax “Not Approvable” For Acute Coronary Syndromes
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.